Fondazione Centro Europeo Nanomedicina c/o Laboratory of Nanostructured Fluorinated Materials (NFMLab), Department of Chemistry, Materials, & Chemical Engineering 'Giulio Natta', Politecnico di Milano, Milan, Italy.
CIC Biomagune, San Sebastian, Spain.
Nanomedicine (Lond). 2015;10(21):3231-47. doi: 10.2217/nnm.15.163. Epub 2015 Oct 16.
Nanomedicine aims to find novel solutions for urgent biomedical needs. Despite this, one of the most challenging hurdles that nanomedicine faces is to successfully target therapeutic nanoparticles to cells of interest in vivo. As for any biomaterials, once in vivo, nanoparticles can interact with plasma biomolecules, forming new entities for which the name protein coronas (PCs) have been coined. The PC can influence the in vivo biological fate of a nanoparticle. Thus for guaranteeing the desired function of an engineered nanomaterial in vivo, it is crucial to dissect its PC in terms of formation and evolution within the body. In this contribution we will review the 'good' and 'bad' sides of the PC, starting from the scientific aspects to the technological applications.
纳米医学旨在为紧急的生物医学需求寻找新的解决方案。尽管如此，纳米医学面临的最具挑战性的障碍之一是成功地将治疗性纳米颗粒靶向到体内感兴趣的细胞。对于任何生物材料而言，一旦进入体内，纳米颗粒就可以与血浆生物分子相互作用，形成新的实体，这些实体被命名为蛋白质冠（PCs）。PC 可以影响纳米颗粒在体内的生物命运。因此，为了保证工程纳米材料在体内的预期功能，必须从体内形成和演变的角度来剖析其 PC。在本综述中，我们将从科学方面到技术应用方面，探讨 PC 的“好”与“坏”。
